What is Exenatide extended-release?
Exenatide extended-release is a long-acting, once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist. It works by mimicking the action of the hormone GLP-1 in the body, helping to increase insulin secretion and decrease glucose production in the liver. This medication helps to improve glycemic control and reduce hemoglobin A1c levels in patients with type 2 diabetes mellitus.
What is Exenatide extended-release used for?
Exenatide extended-release, also known as Byetta or Bydurex in some countries, is an injectable medication that belongs to the class of glucagon-like peptide-1 (GLP-1) receptor agonists. It was first approved by the US FDA in 2005 for the treatment of type 2 diabetes mellitus. Exenatide extended-release works by mimicking the action of a natural hormone in the body called GLP-1, which helps to stimulate insulin secretion and suppress glucagon release from the pancreas.
The medication is designed to be administered via subcutaneous injection once weekly, making it easier for patients to manage their diabetes treatment regimen. Exenatide extended-release has been shown to improve glycemic control in patients with type 2 diabetes by reducing fasting plasma glucose levels and postprandial blood sugar spikes. It also helps to promote weight loss and improve lipid profiles. Studies have demonstrated the efficacy of exenatide extended-release as an adjunct therapy in conjunction with diet, exercise, and other antidiabetic medications to achieve better disease management outcomes for patients with type 2 diabetes.
Exenatide extended-release has been evaluated in various clinical trials involving over 4,000 participants. The most commonly reported side effects associated with this medication include nausea, vomiting, injection site reactions, and diarrhea. Rare but serious adverse events have also been documented, such as pancreatitis, thyroid C-cell tumors, and hypoglycemia when used concurrently with other diabetes medications like sulfonylureas or insulin. As with any prescription medication, the use of exenatide extended-release should be accompanied by careful monitoring and regular follow-up appointments with a healthcare provider to ensure its safe and effective administration.
Exenatide extended-release is typically prescribed for patients who have not achieved adequate glycemic control with lifestyle modifications alone or other antidiabetic medications. The recommended starting dose is 2 mg administered subcutaneously once weekly, and the dose may be adjusted based on individual patient needs and response to treatment.
Exenatide extended-release side effects
• Hypoglycemia (low blood sugar) • Nausea • Vomiting • Diarrhea • Abdominal pain • Injection site reactions • Dizziness • Headache • Fatigue • Muscle weakness • Increased risk of acute kidney injury in patients with severe renal impairment
Disclaimer
The content on this website is for informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. The information provided here is based on general research and may not apply to individual circumstances. We do not guarantee the accuracy or completeness of any content on this website. Always consult with a healthcare professional before making any changes to your medication or health routine.